CADL candeltx.com Final Profit

Corporate emblem and logo of candeltx.com (CADL)

This daily price chart for Candel Therapeutics (CADL) on the GURU.Markets platform reflects profit dynamics, which stand at -0.09. Candel Therapeutics executives are betting on the development of viral immunotherapy methods by optimizing trial phases and seeking strategic partners. Supply reliability is ensured through strict temperature control and an extensive distribution network, enabling the company to effectively implement advanced tumor-fighting methodologies.

CADL (Candel) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company candeltx.com (CADL)

- stock value and consensus price forecast:
Market Price Candel Therapeutics, Inc.|CADL - Price Target Chart
- market capitalization data:
Market Value Candel Therapeutics, Inc.|CADL - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Candel Therapeutics|CADL - Book Capitalization|Market Cap to Net Assets Ratio candeltx.com|CADL - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Candel Therapeutics|CADL - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Candel Therapeutics, Inc.|CADL - Company Aggregate Debts|Debts to Book Value Candel Therapeutics, Inc.|CADL - Company Long-Term Debts|Company Current Liabilities Candel Therapeutics|Quick Ratio candeltx.com
- net income and valuation multiples indicators:
CADL - Company Net Income
Fundamental valuation:CADL Candel
Manufactured product of Candel Therapeutics Inc.

This indicator reflects the bottom-line financial result after deducting all operating and tax expenses. By analyzing the net financial profit of Candel Therapeutics (CADL), an investor assesses capital management efficiency and resilience to cash flow gaps. The metric is sensitive to any fluctuations in revenue and R&D costs. For Candel Therapeutics (CADL), this figure is critical when financing the development of oncolytic viruses. Patent protection for immunotherapies creates the foundation for future growth in profitability.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Accuray, Inc. ARAY|Net Profit SLS|Net Income actuatetherapeutics.com ACTU|Net Profit CTOR (Citius Oncology)|Net Profit TuHURA Biosciences Inc. HURA|TARA - Company Net Income|FATE (Fate Pharma) - Company Profit|WHWK: Net Profit|Company Profit TCRX|CSBR (Champions Oncology Inc) - Net Profit|Company Net Income XBiotech USA XBIT|Company Net Income CEL-SCI Corporation (CVM)|Company Net Income OSTX (OS Therapies, Inc.)|Radiopharm Theranostics Limited - Net Income|Final Profit ARTV|ANL: Net Income|Veru Inc - Profit After Payment of Taxes|TPST: Net Profit|Xilio Therapeutics - Final Profit|RENB (Renovaro Biosciences) - Net Profit|Company Net Income Mural Bio MURA|Company Net Income Kairos Pharma Ltd (KAPA)|OKUR (onkuretherapeutics.com) - Final Profit|Net Profit GDTC (CytoMed Therapeutics Limited)|Net Profit Curis Inc. CRIS|APLM - Company Net Income|Profit After Tax THAR|ADVB: Net Profit|Company Net Income Genprex Inc. (GNPX)|Net Income CLDI|Net Profit Sunshine Biopharma Inc.|Net Income XBIO (Xenetic Biosciences)|Profit After Payment of Taxes SLRX|Net Profit PPBT (Purple Biotech Ltd.)|Net Financial Result American Oncology Network Inc (AONC)|BeOne Medicines - Net Profit|Checkpoint Therapeutics Inc (CKPT) - Net Income|Elevation Oncology, Inc. (ELEV) - Company Net Income|ICAD - Net Financial Result|IKNA (Ikena Oncology Inc.) - Net Profit|Net Income Notable Labs Ltd (NTBL)|Net Profit VIRX|Net Profit MorphoSys Corporation (MOR)|Net Profit NAYA (NAYA Biosciences)|AAPGV: Company Profit